American Healthcare Reit Stock Earnings Reports

American Healthcare REIT (AHR) reported a strong Q1 2026 driven by continued double-digit same-store NOI growth across its portfolio, accretive external acquisitions, disciplined underwriting and strengthened liquidity. Key operational highlights include 12.1% total portfolio same-store NOI growth (ninth consecutive quarter of double-digit growth), Trilogy (ISHC) same-store NOI growth of 14.5% with 91.2% same-store occupancy and Trilogy margins surpassing 20% for the first time since COVID, and SHOP same-store NOI growth of 19.7% with occupancy improving to 88.6%. The investments team closed ~$249M of SHOP acquisitions year-to-date, with a $650M+ pipeline expected to close mostly by the end of Q2/into Q3; development pipeline totals ~$174M (mostly Trilogy campus expansions and IL villas). Financially, normalized FFO (NFFO) was $0.50 per share in Q1 (+31.6% YoY), net debt/annualized EBITDA improved to 3.0x, the unsecured revolver was increased to $800M and ATM forward sale agreements provide meaningful equity capacity (~$527M unsettled forwards, >$1B available program). Management raised full-year 2026 guidance: same-store NOI growth to 9–12% (segment ranges: Trilogy 11–15%, SHOP 15–19%, outpatient medical 0–2%, triple-net 2–3%) and NFFO per share to $2.03–$2.09 (implying ~20% NFFO/share growth at midpoint vs. 2025). Management reiterated operator-first underwriting, selective dealmaking (mostly with existing operators, often off-market), and a capital allocation approach prioritizing retained earnings, dispositions of non-core assets, opportunistic ATM usage and conservative leverage targets to preserve investment-grade metrics while funding a large, accretive pipeline.